John Libbey Eurotext

Bulletin du Cancer

MENU

Perspectives on the oncologist pharmacopœia Volume 90, issue 1, Janvier 2003

Figures

See all figures

Authors
Laboratoire de pharmacologie antitumorale du Centre Oscar-Lambret et Unité 524 Inserm, 1, place de Verdun, 59045 Lille France.

MGI114, ET743, BBR3464, ZD0473, ZD9331, BN80915, J107088, F11782, XR11576, BMS247550, PS341, UCN01, ISIS 3521, STI571, ZD1839, IMC-C225, OSI774, SU5416, DNA minor and major grooves, chimeric proteins, ribonucleotide reductase, topoisomerases, tubuline, proteasome, protein kinase C, bcr-abl, EGF or VEGF tyrosine kinase receptors are code names (somewhat barbarian) and targets for new drugs which will complement the therapeutic arsenal of the twenty-first century oncologist. This review provides a survey their clinical advances.